---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-250165"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2022-09-23T23:59:59+00:00"
generated_at: "2026-06-23T07:47:33.164042+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Helsinn terminates oncology collaboration for infigratinib; BridgeBio continues non-oncology development

## Summary
- QED Therapeutics, BridgeBio subsidiary, received termination notice from Helsinn for infigratinib oncology license agreement.
- Helsinn cites commercial considerations for termination of February 2022 agreement.
- BridgeBio to continue development of infigratinib for achondroplasia worldwide excluding China, Hong Kong, Macau.
- Termination affects commercialization rights for oncology indications worldwide ex-China, Hong Kong, Macau.
- No financial terms disclosed; impact on future revenues uncertain.

## SEC filing metadata
- accession: 0001193125-22-250165
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2022-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000119312522250165/0001193125-22-250165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000119312522250165/d283481d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-250165
- JSON: https://secwatch.observer/filing/0001193125-22-250165.json
- Plain text: https://secwatch.observer/filing/0001193125-22-250165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.